NovoNordisk - Recombinant Insulin (BKC) for Biomanufacturing

Recombinant Insulin is an essential component in modern biomanufacturing processes, developed by Novo Nordisk Pharmatech. It plays a crucial role in enhancing cell proliferation and boosting the production of therapeutic proteins, viral vectors for advanced therapies, and viruses for vaccines. Its unique biological properties make it vital in various cell culture applications, supporting the growth of cells used in monoclonal antibodies, cell and gene therapies, and vaccines. Approved by regulatory bodies globally, this insulin variant is known for its high-quality and consistent performance, proving beneficial in improving the quality and efficiency of cell culture systems. Additionally, its use extends to pluripotent stem cells and cell-based vaccines, contributing to therapies for conditions such as arthritis, cancer, and multiple sclerosis. The product helps accelerate time-to-market for crucial pharmaceuticals, reaching patients worldwide.